Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. - Wikidata - awgldk - TriplyDB

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.

http://www.wikidata.org/entity/Q33796183

about

Management of Chronic Lymphocytic Leukemia in the Elderly Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date Lenalidomide and chronic lymphocytic leukemia New strategies in chronic lymphocytic leukemia: shifting treatment paradigms The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia The biology behind PI3K inhibition in chronic lymphocytic leukaemia Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.Expanding role of lenalidomide in hematologic malignancies Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.Haematological malignancies: at the forefront of immunotherapeutic innovation.Therapeutic advancement of chronic lymphocytic leukemia.Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.Promising therapies for the treatment of chronic lymphocytic leukemia.Emerging immunological drugs for chronic lymphocytic leukemia.Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?The clinical safety of ibrutinib in chronic lymphocytic leukemia.Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.Chronic lymphocytic leukemia (CLL)-Then and now.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Magic pills: new oral drugs to treat chronic lymphocytic leukemia.The safety profile of monoclonal antibodies for chronic lymphocytic leukemia.What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.Mobilization of human immature hematopoietic progenitors through combinatory use of bortezomib and immunomodulatory drugs.Chronic lymphocytic leukaemia

P2860

Q26775983-89FAA9A1-CEC2-4C80-817E-2EE89B2588EC Q26798062-5B14F00E-2F61-4897-BFE2-C25085C12586 Q26823597-76859A89-179A-405E-997C-C85EF61B34ED Q26828496-E1A16BA7-3781-4B17-8783-37D083CE3421 Q28075683-82E1A82D-6135-4CF8-80A0-791D045013BF Q28083266-3E32E95B-4512-45F5-9D7D-18B92067204C Q33429161-CA38E970-D641-4528-A072-7D1AE46836C3 Q33436535-4537F1E5-01E6-41A8-98FD-2162CE9FAB34 Q34440110-57DF19C6-B59E-4FEB-8F25-B69751C03D26 Q35592305-80DF4ABD-2831-4F79-8389-DF57BF8062C4 Q35812675-32CA9AFE-8AC9-48C1-88F9-02EFD0A5EC92 Q35880618-AC7FB21A-ACBF-404F-9988-1A880BE29A76 Q36300303-A9B6E7A5-05B0-441C-B5B0-DC842C71FF31 Q36725307-DD6BCD90-5598-4438-8049-C885676CEECD Q38366441-599461FA-7077-4228-9B53-4DDA54B0EB18 Q38543771-67FC10AB-A3C5-46CC-A829-EF561A31F077 Q38550810-4C674287-3A33-4A18-AEA9-0CE2173E0459 Q38573785-87839331-17DA-4082-A655-E0B341BE24BE Q38584629-45937C63-7D16-4C65-8973-F5D8DD79D619 Q38594364-41EE9016-A19F-42BA-87E2-E6CCE9353128 Q38675358-AD3386CE-84D6-43F2-9051-3736EDF84600 Q38818283-A880E487-E115-4BDA-BCD9-6748BFF23BBD Q38943877-8215FC6B-0B86-4927-B87F-C161CBDB9F32 Q39018189-4736171A-4E76-4979-97E6-61B13462DBB7 Q39154057-FEADDE7C-A9E9-4885-BD86-456554943128 Q50864223-732AD29D-40FC-47F7-B1EB-9099487189FB Q51007218-CF6A6745-0B7D-4158-A424-9BCE01BAE922 Q51311518-E57F54F8-C657-4B69-AC0F-AA1A385DB0A4 Q56270980-D18F98D0-E3C1-4C14-B1D3-B9AFCA1B4D1D

P2860

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.

http://www.wikidata.org/entity/Q33796183

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Lenalidomide and rituximab for ...... leukemia research consortium.

@ast

Lenalidomide and rituximab for ...... leukemia research consortium.

@en

type

label

Lenalidomide and rituximab for ...... leukemia research consortium.

@ast

Lenalidomide and rituximab for ...... leukemia research consortium.

@en

prefLabel

Lenalidomide and rituximab for ...... leukemia research consortium.

@ast

Lenalidomide and rituximab for ...... leukemia research consortium.

@en

P1433

Q33796183-1E2779BD-BAEA-4B7E-97EA-DC0E48591617

P1476

Q33796183-666B07B2-4E57-4E5D-B62C-571BFC9654BF

P2093

Q33796183-111C11BB-2546-435B-89A4-C703B7E820DB

Q33796183-22BD762F-2164-4497-B054-3F46551CD96E

Q33796183-266144B8-B1B3-4E08-B42D-4118D81B99DE

Q33796183-2A629EB2-52A8-4665-989C-B72283AF2246

Q33796183-45AADB1F-9551-4C99-99BE-6FA2B5BF70E1

Q33796183-58B39955-355D-4101-B98C-5C542FBDA27B

Q33796183-5ECB8CB8-F96D-44AA-AB84-D0DCCD4BBA82

Q33796183-AFC83E22-53C0-4CAA-97D9-9A87D9EA9CE1

Q33796183-B9716F3D-68AE-48B7-BD62-4AE8C79B21DE

Q33796183-C771AA5B-DB73-4729-89AB-CEF88A47D8C9

P2860

Q33796183-09BF1D49-64A2-4CA7-A29C-574326D62EF9

Q33796183-16C60CBD-69E7-4C8D-B3EB-2FCAFBF2BA5C

Q33796183-1F40FEC5-D17B-482F-B683-EF86A14027AF

Q33796183-21040F0A-BC88-4865-BA77-97D6A2BCCBCD

Q33796183-21E84AE9-4C09-4015-80D8-F286DBAA11BD

Q33796183-237BBF12-8184-45CC-A74B-FD5C0D684808

Q33796183-2E3678FF-58DA-49B7-97F6-99D9E7D843FF

Q33796183-367AADC6-5E6B-4E53-8A45-46D32B95B9E6

Q33796183-59402805-A83C-435F-AE16-39B837FA1934

Q33796183-5DCDBB28-7802-410E-A4B7-1A630978EF40

P304

Q33796183-3AC1B757-8E59-40D8-894B-1CE780DD93EF

P31

Q33796183-834F7590-B158-435E-93C4-5F3338CBEA6A

P356

Q33796183-47D42B0A-B1FC-4E2D-968D-D5D87E03B9E3

P407

Q33796183-FDF87037-7614-42F9-B523-B9182160B8E3

P433

Q33796183-53BD0E73-E025-4BBD-941A-0C3244A1D6A8

P478

Q33796183-0D06D2AE-7ABC-4EDE-8AB2-5FC264377EA0

P50

Q33796183-2E5DD4E7-582E-402A-A1C8-9245107FE5A0

Q33796183-B3C021CE-5CB8-452A-89B9-6DE8F1714430

P577

Q33796183-C81B9B62-C62D-4F46-B273-6FBFD854AB19

P698

Q33796183-8F1DA416-7270-4378-A788-5AD1AE1489CA

P921

Q33796183-60DE64ED-4B43-4262-B0C2-BD7163D7CFF6

Q33796183-E9AF9187-1BA7-4902-949F-31C34C724F4F

Q33796183-FEAC8F0C-31D5-4702-9DB8-2A82FC51137B

P932

Q33796183-2C4697EE-2107-4585-AEB6-288AC4BB23C3

P356

JCO.2013.51.5890

P1433

Journal of Clinical Oncology

P1476

Lenalidomide and rituximab for ...... leukemia research consortium.

@en

P2093

Amy J Johnson

http://www.w3.org/2001/XMLSchema#string

Andrew Greaves

http://www.w3.org/2001/XMLSchema#string

Danelle F James

http://www.w3.org/2001/XMLSchema#string

Donna Neuberg

http://www.w3.org/2001/XMLSchema#string

Januario E Castro

http://www.w3.org/2001/XMLSchema#string

Jennifer R Brown

http://www.w3.org/2001/XMLSchema#string

Kanti R Rai

http://www.w3.org/2001/XMLSchema#string

Laura Z Rassenti

http://www.w3.org/2001/XMLSchema#string

Lillian Werner

http://www.w3.org/2001/XMLSchema#string

Thomas J Kipps

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

P304

2067-2073

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.51.5890

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Jacqueline Barrientos

William G Wierda

P577

2014-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24868031

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

4067945

http://www.w3.org/2001/XMLSchema#string